Clinical Trials Logo

Clinical Trial Summary

NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer


Clinical Trial Description

NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer Will be intra-peritoneal infusion in Stage 1 and combined with intra-venous infusion in Stage 2. While in Stage 3, the investigators will expand to other cancer type at certain situation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05213195
Study type Interventional
Source Zhejiang University
Contact Weijia Fang, MD
Phone 13758211655
Email [email protected]
Status Recruiting
Phase Phase 1
Start date December 10, 2021
Completion date June 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04527068 - QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer Phase 2
Recruiting NCT05248048 - NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer Early Phase 1
Active, not recruiting NCT04737187 - Phase III Study of Trifluridine/Tipiracil in Combination With Bevacizumab vs Trifluridine/Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer Phase 3
Recruiting NCT05205330 - A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients Phase 1/Phase 2
Completed NCT02860546 - A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC Phase 2